Abstract: A layered body, which has a change in texture derived from zirconia, particularly a change in translucency and is suitable as a dental prosthetic member, a precursor thereof, or a method for producing these. The layered body has a structure in which two or more layers containing zirconia containing a stabilizer are layered, the layered body including at least: a first layer containing zirconia having a stabilizer content of higher than or equal to 4 mol %; and a second layer containing zirconia having a stabilizer content different from that of the zirconia contained in the first layer. At least one layer contains one or more elements capable of coloring zirconia.

Abstract: To provide at least one of: a powder composition from which a calcined body with similar processability can be produced without requiring the application of different forming conditions and calcination conditions for each composition; a method for producing the powder composition; a calcined body produced from the powder composition; a method for producing the calcined body; and uses thereof. A powder composition including: two or more types of zirconia in which a lanthanoid rare-earth element is dissolved; a transition metal element other than zirconium and hafnium; and a remainder composed of zirconia stabilized only by one or more selected from the group consisting of yttrium, calcium and magnesium, wherein a different lanthanoid rare-earth element is dissolved in each zirconia in which the lanthanoid rare-earth element is dissolved, and a transition metal element content is 1500 ppm or less.

Abstract: Communication program code is communication program code incorporated into an application and continuously displays a startup button on an application screen, operates as a function of the application when the startup button is operated, and allows a talk between a user and a developer. A communication function allows the developer and the user to talk in real time, and hence the user of the application can easily give feedback, such as report of usability and problems, to the developer in real time.

Abstract: A coating agent for a pharmaceutical solid preparation imparts an unpackaged pharmaceutical solid preparation with excellent barrier properties equivalent to those of a PTP sheet without affecting the disintegration properties of the pharmaceutical solid preparation. The coating agent for a pharmaceutical solid preparation includes a polyethylene glycol having an average molecular weight of 950 to 25,000 and a swelling clay, wherein the mass ratio of the polyethylene glycol and the swelling clay is 2:8 to 6:4.

Abstract: A film coating agent for a solid formulation includes a water-soluble cellulose derivative, swelling clay, a cationic surfactant, and a fatty acid, wherein mass ratio of the swelling clay to the water-soluble cellulose derivative is 2:8 to 8:2, and content of the cationic surfactant is not less than 0.5 equivalents and not more than 3.0 equivalents relative to a cation exchange equivalent of the swelling clay.

Abstract: A coating material for a solid formulation is capable of stably retaining the effective ingredient in the solid formulation for a prolonged period even in unpacked condition in such a manner that the solid formulation can be used in a single-dose formulation. The coating material for a solid formulation includes a high hydrogen-bonding resin and a swelling clay and, when coated on a solid formulation and dried, forms a coating film in which the laminated structures of the aforementioned swelling clay are oriented planarly and dispersed in a network fashion.

Abstract: A method improves stability of drugs in a solid pharmaceutical formulation against oxygen and water vapor by coating the solid pharmaceutical formulation with a coating material including a high hydrogen-bonding resin and a swelling clay.

Abstract: A montelukast-containing coated solid preparation can be applied to one-dose package, wherein the humidity stability of montelukast or a pharmacologically acceptable salt thereof contained therein is maintained even when the preparation is unpacked. A coated solid preparation contains as an active ingredient montelukast or a pharmacologically acceptable salt thereof and is coated with a coating layer comprising polyvinyl alcohol and swelling clay, wherein the mass ratio of the above-described polyvinyl alcohol to the above-described swelling clay in the above-described coating layer is 8:2 to 3:7.

Abstract: A coating agent for a pharmaceutical solid preparation imparts an unpackaged pharmaceutical solid preparation with excellent barrier properties equivalent to those of a PTP sheet without affecting the disintegration properties of the pharmaceutical solid preparation. The coating agent for a pharmaceutical solid preparation includes a polyethylene glycol having an average molecular weight of 950 to 25,000 and a swelling clay, wherein the mass ratio of the polyethylene glycol and the swelling clay is 2:8 to 6:4.

Abstract: A montelukast-containing coated solid preparation can be applied to one-dose package, wherein the humidity stability of montelukast or a pharmacologically acceptable salt thereof contained therein is maintained even when the preparation is unpacked. A coated solid preparation contains as an active ingredient montelukast or a pharmacologically acceptable salt thereof and is coated with a coating layer comprising polyvinyl alcohol and swelling clay, wherein the mass ratio of the above-described polyvinyl alcohol to the above-described swelling clay in the above-described coating layer is 8:2 to 3:7.

Abstract: A film coating agent for a solid formulation includes a water-soluble cellulose derivative, swelling clay, a cationic surfactant, and a fatty acid, wherein mass ratio of the swelling clay to the water-soluble cellulose derivative is 2:8 to 8:2, and content of the cationic surfactant is not less than 0.5 equivalents and not more than 3.0 equivalents relative to a cation exchange equivalent of the swelling clay.

Abstract: A coating material for a solid formulation is capable of stably retaining the effective ingredient in the solid formulation for a prolonged period even in unpacked condition in such a manner that the solid formulation can be used in a single-dose formulation. The coating material for a solid formulation includes a high hydrogen-bonding resin and a swelling clay and, when coated on a solid formulation and dried, forms a coating film in which the laminated structures of the aforementioned swelling clay are oriented planarly and dispersed in a network fashion.